Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1 12Phase 1/2 5Phase EARLY_PHASE1 3Phase 3 1Phase 2/3 1

Status

Recruiting 3Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Multiple Myeloma 1Hematologic Neoplasms 1Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 17Cyclophosphamide 16fludarabine 12Specimen Handling 12Fluorodeoxyglucose F18 7pembrolizumab 6X-Rays 6Nivolumab 6Temozolomide 5Radiotherapy 5Immunotherapy, Adoptive 5lenvatinib 4Paclitaxel 4Leukapheresis 4Immune Checkpoint Inhibitors 4Etoposide 4Cisplatin 4Carboplatin 4ruxolitinib 3fluciclovine F-18 3Tirzepatide 3Surgical Procedures, Operative 3Doxorubicin 3Dasatinib 3Cholecalciferol 3Biopsy 368Ga-FAPI 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3tislelizumab 2palbociclib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Recruiting × ruxolitinib × Clear all
NCT04744116 2026-05-05

Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Recruiting
24 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT06008275 2025-11-10

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

Baylor Research Institute

Phase EARLY_PHASE1 Recruiting
20 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06209606 2024-12-17

Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

Oncotherapeutics

Phase EARLY_PHASE1 Recruiting
30 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡